Quick Answer
Eton Pharmaceuticals, Inc. reported Total Assets of $92.11 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +21.0% in Total Assets from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $7.53 million | Q1 2019: $23.02 million | Q2 2019: $18.24 million | Q3 2019: $13.51 million | Q1 2020: $17.24 million | Q2 2020: $14.56 million | Q3 2020: $11.40 million | Q1 2021: $31.19 million | Q2 2021: $29.91 million | Q3 2021: $26.61 million | Q1 2022: $23.20 million | Q2 2022: $23.05 million | Q3 2022: $21.52 million | Q1 2023: $23.93 million | Q2 2023: $30.93 million | Q3 2023: $31.53 million | Q1 2024: $30.79 million | Q2 2024: $31.82 million | Q3 2024: $35.84 million | Q1 2025: $84.03 million | Q2 2025: $101.68 million | Q3 2025: $104.51 million.
- Over the full 9 years of available data (2017 to 2025), Eton Pharmaceuticals, Inc.'s Total Assets has grown by 585.2%.
- Historical annual values: Fiscal year 2025: $92.11 million | Fiscal year 2024: $76.12 million | Fiscal year 2023: $31.74 million | Fiscal year 2022: $25.03 million | Fiscal year 2021: $27.47 million | Fiscal year 2020: $26.32 million | Fiscal year 2019: $17.07 million | Fiscal year 2018: $28.33 million | Fiscal year 2017: $13.44 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: